[anecdote] GHRH analog classically stacked with a GHRP to extend GH in the system. [note] Status in flux — removed from compounding in-episode, but the recorded intro update reports CJC-1295 re-allowed for US prescription. — Koniver 00:03–00:04, 00:54
[anecdote-bb] No-DAC 150–300 mcg SubQ ≤3×/day; DAC version 1–2 mg once weekly. Popular minimal-injection combo: CJC-1295-DAC weekly + MK-677 nightly. — Vigorous Steve
[educational]With-DAC vs without-DAC are different peptides. Literature ‘CJC-1295’ = with DAC (maleimidopropionic acid → albumin binding → t½ 5.8–8.1 days), which raises basal/trough GH ~7.5× while leaving pulses unchanged — non-physiologic (aging is lost amplitude, not low basal) → off the table for health/longevity. The 4 aa changes give ~4× sermorelin potency (both forms). A with-DAC phase-2 was terminated unpublished after a participant death (deemed unrelated cardiac). — GH selection guide
Physician protocols
[protocol]No-DAC (modified GRF 1-29) is the longevity-oriented form here (distinct from the long-acting DAC version): no human studies → speculative; ~4× sermorelin potency → start ~100–125 mcg, max ~200–250 mcg; half-life ~20–50 min. Night dosing; the GHRH that’s most reasonable to take 2×/day with ipamorelin. — GH admin guide
Practical notes
[warning] Long-acting via a DAC (1–2×/week), but a death occurred in a clinical trial (cardiovascular) and it causes fluid retention; no clear reason to choose it over sermorelin/tesamorelin until safety resolves. (Contrast: Koniver notes it was later re-allowed.) — Huberman 00:50–00:52, 00:59